Frank Maldarelli

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint HIV-1 Fitness and Replication Capacity: What Are They and Can They Help in Patient Management?
    Frank Maldarelli
    HIV 1 Drug Resistance Program, National Cancer Institute, National Institutes of Health, Building 10, Room 10S255, Bethesda, MD 20892, USA
    Curr Infect Dis Rep 5:77-84. 2003
  2. ncbi request reprint Prion Diseases: Update on Mad Cow Disease, Variant Creutzfeldt-Jakob Disease, and the Transmissible Spongiform Encephalopathies
    Jacqueline Janka
    NCI, National Institutes of Health, Building 10, Room 12S245, Bethesda, MD 20892, USA
    Curr Infect Dis Rep 6:305-315. 2004
  3. pmc HIV populations are large and accumulate high genetic diversity in a nonlinear fashion
    Frank Maldarelli
    HIV Drug Resistance Program, NCI Frederick, NIH, Frederick, Maryland, USA
    J Virol 87:10313-23. 2013
  4. doi request reprint Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Curr Opin HIV AIDS 6:49-56. 2011
  5. pmc ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS Pathog 3:e46. 2007
  6. pmc RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy
    Wei Shao
    Advanced Biomedical Computing Center, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD, USA
    Retrovirology 6:101. 2009
  7. ncbi request reprint Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 20:701-10. 2006
  8. pmc Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase
    Mary Kearney
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 22:497-501. 2008
  9. pmc Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy
    Mary Kearney
    HIV Drug Resistance Program, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 109, Frederick, MD 21702 1201, USA
    J Virol 85:1067-76. 2011
  10. pmc Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication
    Andrea Galli
    HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    J Virol 84:7651-61. 2010

Detail Information

Publications50

  1. ncbi request reprint HIV-1 Fitness and Replication Capacity: What Are They and Can They Help in Patient Management?
    Frank Maldarelli
    HIV 1 Drug Resistance Program, National Cancer Institute, National Institutes of Health, Building 10, Room 10S255, Bethesda, MD 20892, USA
    Curr Infect Dis Rep 5:77-84. 2003
    ..In this review we explore the experimental basis for replication capacity measurements and potential clinical applications of this methodology...
  2. ncbi request reprint Prion Diseases: Update on Mad Cow Disease, Variant Creutzfeldt-Jakob Disease, and the Transmissible Spongiform Encephalopathies
    Jacqueline Janka
    NCI, National Institutes of Health, Building 10, Room 12S245, Bethesda, MD 20892, USA
    Curr Infect Dis Rep 6:305-315. 2004
    ..This paper reviews recent advances that have shed new light on the nature of prions and TSEs...
  3. pmc HIV populations are large and accumulate high genetic diversity in a nonlinear fashion
    Frank Maldarelli
    HIV Drug Resistance Program, NCI Frederick, NIH, Frederick, Maryland, USA
    J Virol 87:10313-23. 2013
    ....
  4. doi request reprint Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Curr Opin HIV AIDS 6:49-56. 2011
    ....
  5. pmc ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
    Frank Maldarelli
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS Pathog 3:e46. 2007
    ..These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy...
  6. pmc RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy
    Wei Shao
    Advanced Biomedical Computing Center, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD, USA
    Retrovirology 6:101. 2009
    ..Bioinformatics tools were constructed to trace individual genomes from the beginning of infection to the end of the treatment...
  7. ncbi request reprint Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 20:701-10. 2006
    ..Understanding the selection and decay of drug-resistant HIV-1 variants is important for designing optimal antiretroviral therapy...
  8. pmc Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase
    Mary Kearney
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    AIDS 22:497-501. 2008
    ..Failure of antiretroviral therapy may result from the selection of pre-existing, drug-resistant HIV-1 variants, but the frequency and type of such variants have not been defined...
  9. pmc Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy
    Mary Kearney
    HIV Drug Resistance Program, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 109, Frederick, MD 21702 1201, USA
    J Virol 85:1067-76. 2011
    ....
  10. pmc Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication
    Andrea Galli
    HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    J Virol 84:7651-61. 2010
    ..Therefore, the ability of the recombinants to replicate is the major barrier for many of these viruses...
  11. pmc Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase
    Valerie F Boltz
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, USA
    J Virol 86:12525-30. 2012
    ..The rapid increase of 103N mutations from <0.001% to 20% of the viral population indicates that the replicating virus population size in RT-SHIV-infected macaques must be 10(6) or more infected cells per replication cycle...
  12. pmc Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine
    Krista A Delviks-Frankenberry
    Viral Mutation Section, Host Virus Interaction Branch, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    J Virol 83:8502-13. 2009
    ....
  13. pmc Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 43:406-13. 2005
    ..In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis...
  14. pmc Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial
    Brian O Porter
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20982, USA
    AIDS 23:203-12. 2009
    ..To evaluate whether interleukin (IL)-2 in patients with chronic HIV infection can maintain CD4 T cell counts during 6 months of HAART interruption...
  15. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children
    Rachel I Gafni
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Pediatrics 118:e711-8. 2006
    ..We hypothesized that, given the higher rate of bone turnover that is associated with normal skeletal growth, the potential for TDF-related bone toxicity may be greater in children than in adults...
  16. pmc Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 105:3879-84. 2008
    ..These data suggest that low-level persistent viremia appears to arise from at least two cell compartments, one in which viral production decays over time and a second in which viral production remains stable for at least 7 years...
  17. pmc Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance
    Galina N Nikolenko
    Viral Mutation Section and Host Virus Interaction Unit, HIV Drug Resistance Program, and Data Management Services, Inc, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:317-22. 2007
    ..These results indicate that mutations in the C-terminal domain of RT significantly enhance clinical NRTI resistance and should be considered in genotypic and phenotypic drug resistance studies...
  18. doi request reprint Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women
    Sarah Palmer
    HIV Drug Resistance Program, NCI, NIH, Frederick, MD, USA
    Antivir Ther 17:327-36. 2012
    ..To detect NVP resistance with greater sensitivity, we analysed TOPS samples by allele-specific real-time PCR (ASP)...
  19. pmc Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor
    Jianbo Chen
    HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, MD 21702, USA
    J Virol 79:4140-9. 2005
    ..Therefore, these results support our hypothesis that multiple virions are transmitted from DCs to T cells during cell-mediated HIV-1 transmission...
  20. ncbi request reprint A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  21. pmc Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy
    Elizabeth Nies-Kraske
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, USA
    J Infect Dis 199:1648-56. 2009
    ..All 4 patients had significant fibrosis of the T cell zone of lymphoid tissue, which appeared to be an important factor in the failure to reconstitute T cells...
  22. pmc Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA
    Wei Shao
    Advanced Biomedical Computing Center, SAIC Frederick, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, USA
    Retrovirology 10:18. 2013
    ..We evaluated the performance of 454 sequencing for characterizing HIV populations with defined allele frequencies...
  23. pmc Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision
    Galina N Nikolenko
    Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 102:2093-8. 2005
    ....
  24. ncbi request reprint Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals
    Shyam Kottilil
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    HIV Clin Trials 5:25-32. 2004
    ..We examined the long-term effect of controlling HIV infection with highly active antiretroviral therapy (HAART) on HCV viremia among co-infected patients...
  25. pmc Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design
    Valerie F Boltz
    HIV Drug Resistance Program, NCI, NIH, Frederick, MD, United States
    J Virol Methods 164:122-6. 2010
    ..The goals of this study were to quantify this effect and then to improve assay performance...
  26. pmc Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy
    Zandrea Ambrose
    HIV Drug Resistance Program, National Cancer Institute, Building 535, Room 123, Frederick, MD 21702, USA
    J Virol 81:12145-55. 2007
    ..By contrast, ART effectively suppressed RT-SHIV in 5/6 animals. These data indicate that suboptimal therapy facilitates HIV-1 drug resistance and suggest that this model can be used to investigate persisting viral reservoirs...
  27. pmc New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    J Clin Microbiol 41:4531-6. 2003
    ....
  28. pmc Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA
    Valerie F Boltz
    HIV Dynamics and Replication Program, CCR, National Cancer Institute, NIH, Translational Research Unit, 105 Boyles Street, Building 535 Room 111, Frederick, MD, 21702 1201, USA
    Retrovirology 13:87. 2016
    ....
  29. pmc Retrovirus Integration Database (RID): a public database for retroviral insertion sites into host genomes
    Wei Shao
    Advanced Biomedical Computing Center, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research FNLCR, Frederick, MD, USA
    Retrovirology 13:47. 2016
    ..The website is robust, user friendly, and allows users to query the database and analyze the data dynamically...
  30. pmc Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance
    Krista A Delviks-Frankenberry
    Viral Mutation Section, HIV Drug Resistance Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
    Virology 435:433-41. 2013
    ..These results indicate that selection of CN mutations in treatment-experienced patients also occurs in subtype-C-infected patients and are likely to provide valuable information in predicting clinical RTI resistance...
  31. pmc Multiple Origins of Virus Persistence during Natural Control of HIV Infection
    Eli A Boritz
    Human Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    Cell 166:1004-15. 2016
    ..Thus, HIV replication in lymphoid tissue, clonal expansion of infected cells, and recirculation of recently infected cells act together to maintain the virus in HIV controllers despite effective antiviral immunity. ..
  32. pmc Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays
    Helene Mens
    Virology Core, HIV Drug Resistance Program, NCI Frederick, MD, USA
    J Vis Exp . 2011
    ..However, the amplification success of SCA and SGS depend on primer design. Both assays were developed for HIV-1 subtype B, but can be adapted for other subtypes and other regions of the genome by changing primers, probes, and standards...
  33. pmc Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy
    Mary F Kearney
    HIV 1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS Pathog 10:e1004010. 2014
    ....
  34. pmc Multiple sources of contamination in samples from patients reported to have XMRV infection
    Mary F Kearney
    HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland, United States of America
    PLoS ONE 7:e30889. 2012
    ....
  35. ncbi request reprint Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
    Rohan Hazra
    HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Pediatrics 116:e846-54. 2005
    ..We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children...
  36. pmc Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1
    Arman A Bashirova
    Laboratory of Genomic Diversity, SAIC Frederick, Inc, National Cancer Institute, Frederick, Maryland 21702, USA
    J Virol 80:6757-63. 2006
    ..The data raise the hypothesis that noncoding variation in TSG101 affects the efficiency of TSG101-mediated release of viral particles from infected cells, thereby altering levels of plasma viral load and subsequent disease progression...
  37. ncbi request reprint Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function
    Shyam Kottilil
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases NIH, 9000 Wiscoinsin Avenue, Building 10, Room 6A08A, Bethesda, MD 20892, USA
    J Infect Dis 187:1038-45. 2003
    ....
  38. pmc Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
    Stephen A Migueles
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 29:1009-21. 2008
    ..They also demonstrate that lytic granule contents of memory cells are a critical determinant of cytotoxicity that must be induced for maximal per-cell killing capacity...
  39. doi request reprint CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7
    Marta Catalfamo
    Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:2106-16. 2011
    ..CD4 T cell subsets also showed enhanced STAT1 phosphorylation in response to exogenous IL-7...
  40. pmc Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir
    Roshan Ramanathan
    Clinical Parasitology Unit and Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 47:e97-9. 2008
    ..This case highlights the potential of ritonavir interactions even with local injections of a corticosteroid...
  41. pmc Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy
    James M Mikula
    Clinical Research Directorate Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
    Antivir Ther 21:553-558. 2016
    ..TAF may represent a useful option to maximally suppress HIV in patients with these complications...
  42. pmc Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo
    Francesco R Simonetti
    HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD 21702 Department of Biomedical and Clinical Sciences L Sacco, University of Milan, 20157 Milan, Italy
    Proc Natl Acad Sci U S A 113:1883-8. 2016
    ..Cells containing the intact provirus were widely distributed and significantly enriched in cancer metastases. These results show that clonally expanded CD4(+)T cells can be a reservoir of infectious HIV-1. ..
  43. doi request reprint Single-copy quantification of HIV-1 in clinical samples
    Ann Wiegand
    HIV Drug Resistance Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
    Methods Mol Biol 1087:251-60. 2014
    ..Here we describe in detail an assay for HIV-1 RNA with single-copy sensitivity. ..
  44. pmc Variation in the major surface glycoprotein genes in Pneumocystis jirovecii
    Geetha Kutty
    Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Infect Dis 198:741-9. 2008
    ..Increased diversity in the Msg repertoire, generated in part by recombination, increases the potential for antigenic variation in this abundant surface protein...
  45. pmc Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways
    Que Dang
    HIV Drug Resistance Program and Data Management Services, National Cancer Institute Frederick, National Institutes of Health, MD 21702, USA
    Proc Natl Acad Sci U S A 101:632-7. 2004
    ..Frequent double HIV-1 infections in infected individuals would allow the generation of recombinant viruses that could then affect their pathogenesis and evolution...
  46. pmc Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA
    Zachary Klase
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 10:e1003997. 2014
    ..This work highlights the therapeutic potential of inhibitors of RUNX1 to re-activate virus and aid in clearance of HIV-1. ..
  47. pmc Clinical management of HIV drug resistance
    Karoll J Cortez
    HIV Drug Resistance Program, NCI, NIH, Bethesda, MD 20892, USA
    Viruses 3:347-78. 2011
    ..This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy...
  48. pmc XMRV: a new virus in prostate cancer?
    Amanda L Aloia
    HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Cancer Res 70:10028-33. 2010
    ..It is possible that XMRV is not actually circulating in the human population; even if it is, the data do not seem to support a causal role for this virus in PCa...
  49. ncbi request reprint Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Caryn Morse
    J Infect Dis 195:318-21. 2007
  50. ncbi request reprint Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy
    Peter A Sklar
    AIDS 19:1109-11. 2005